Plasma pTau181/pTau217 Assays for Non-Invasive Alzheimer’s Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing early-stage Alzheimer's disease are invasive and expensive, such as PET imaging and spinal taps, and there is a need for non-invasive and highly sensitive methods to detect tau phosphorylation for early diagnosis and monitoring cognitive decline.
Innovation Solution
The development of methods and kits for detecting phosphorylated tau (pTau181 and pTau217) using capture and detection reagents to form complexes, allowing for the detection of pTau levels in samples from individuals with mild cognitive impairment or subjective cognitive complaints, enabling early diagnosis and monitoring of cognitive decline.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PET imaging and spinal tap are used to diagnose Alzheimer's disease, then diagnostic accuracy is improved, but invasiveness and cost increase
Solution Approach 1:
The patent uses plasma as an intermediary medium to detect Alzheimer's disease biomarkers. Instead of directly invading the brain or spinal cord to obtain CSF, the method detects phosphorylated tau proteins in plasma, which serve as a proxy indicator of brain pathology, thereby achieving non-invasive diagnosis with maintained diagnostic accuracy
Solution Approach 2:
The patent replaces mechanical invasive procedures (spinal tap, PET imaging) with a biochemical detection system. By using immunoassays to detect specific protein phosphorylation states in plasma, the method substitutes physical invasion with molecular detection, eliminating invasiveness while maintaining diagnostic precision
2Measurement precision
If PET imaging and spinal tap are used to diagnose Alzheimer's disease, then diagnostic accuracy is improved, but cost increases
Solution Approach 1:
The patent employs cost-effective plasma samples and standardized immunoassay kits instead of expensive PET scanners and complex spinal tap procedures. The method uses readily available plasma from routine blood draws combined with accessible laboratory testing, significantly reducing the financial barrier to early Alzheimer's diagnosis while maintaining diagnostic reliability
3Measurement precision
If conventional methods are used for early diagnosis, then diagnostic capability is provided, but sensitivity and specificity for early stage pathology are insufficient
Solution Approach 1:
The patent focuses detection on specific local characteristics of tau proteins - specifically phosphorylation at particular sites (such as Serine 396, Threonine 181, Threonine 217). By targeting these specific molecular modifications rather than measuring total tau or using generic biomarkers, the method achieves high sensitivity and specificity for early-stage Alzheimer's pathology before clinical symptoms manifest
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods provide highly sensitive and specific detection of pTau levels, accurately distinguishing between stable and declining cognitive states, and monitoring response to treatment, facilitating early intervention and enrollment in clinical trials.
Implementation Method 1
contacting the sample with: (i) a first capture reagent that binds tau; (ii) a second capture reagent that binds tau; (iii) a detection reagent that binds pTau181 or pTau217, thereby forming a complex comprising the first and second capture reagents, pTau181 or pTau217, and the detection reagent
Data Source
AI summary
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.